Professionals in the Pharmaceutical Industry Gather at EffPha to Exchange Current Status and Trends in Drug Development

Several distinguished experts in the biotechnology and pharmaceutical fields visited EffPha in mid-April this year. We had our valued guests, including Dr. Jo Shen (Venture Partner of Vivo Capital LLC), Dr. Chu-Chung Lin (Founder and CEO of Anhorn Medicines Co., Ltd.), Dr. Ae-June Wang (Founder and President of Andros Pharmaceuticals Co., Ltd.), Dr. Jason Liao (Senior Director of CEO Office-Data Science of PharmaEssentia Corp.), Dr. Sheena Lin (Principal Scientist of CEO Office of PharmaEssentia Corp.), Dr. Shian-Jy (Jassy) Wang (Founder and President of MegaPro Biomedical Co., Ltd.), Dr. I-Ju Chen (Senior Regulatory Project Manager of AnnJi Pharmaceutical Co., Ltd.), and Jenny Chang (Medical Affairs Director of AnnJi Pharmaceutical Co., Ltd.), gather at EffPha, where on that day they exchanged perspectives with EffPha’s President and CEO, Dr. Frank Shen and EffPha team on the status and bottlenecks in drug development in Taiwan.

During the visit, the experts had an in-depth discussion with the EffPha team. They shared issues in drug development such as regulatory dossier preparations, approval of regulatory applications, and the difficulties of international multi-center clinical trials they have encountered. Dr. Frank Shen shared his insights in drug development based on over 30 years of work experience in global pharmaceutical companies with the experts. He emphasized that an experienced and talented drug development team can not only provide decision-makers with the best strategies of drug development, advise and direct clinical operations, but also identify potential risks in drug development, which allows them to further plan risk management or adjust the direction of product development. Therefore, it would help shorten drug development timelines and mitigate risks for biotech and pharmaceutical companies, allocating development resources more efficiently.

EffPha deeply understands the actual needs of our clients, and the EffPha team consists of experts with many years of drug development experience from global pharmaceutical companies. That EffPha is an expert-based CRO is the brand positioning by providing advice based on practical industry experience from domestic and international new drug development companies. The EffPha team is insightful, and stays updated with regulatory review trends. We excel at proposing the most suitable drug development strategies, designing clinical trials with high success rates, and providing high-quality clinical trial monitoring and management for the purpose of providing clients with the most efficient services. In recent years, clinical trials have tended to be conducted in multiple countries. In response, EffPha has set its sights on the global market. EffPha has taken the initiative to build a global presence, expand CRO services for international multi-center clinical trials, and move forward with our long-term collaborative pharmaceutical partners.

Through the day’s exciting discussions and sharing of industry experience, we saw the brilliance and wisdom produced by the biotech companies, pharmaceutical companies, and CROs. EffPha looks forward to finding the best drug development strategies in multiple fields by working with our expert partners in the industry, government and academics to stand out and shine brightly in the world.